Computed tomography study of the effect of orlistat on visceral adipose tissue volume in obese subjects

Israel Medical Association Journal

Volumn 12, Issue 4, 2010, Pages 199-202

  Dicker, Dror ^a   Herskovitz, Pearl ^a   Katz, Miryam ^a   Atar, Eli ^a   Bachar, Gil N ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

Adipose tissue; Cardiovascular risk; Computed tomography; Obesity; Orlistat

Indexed keywords

GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; ANTIOBESITY AGENT; LACTONE;

ADULT; AGED; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CASE STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTRAABDOMINAL FAT; LOW CALORY DIET; MALE; OBESITY; PROSPECTIVE STUDY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SUBCUTANEOUS FAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECTS; MIDDLE AGED; PROCEDURES; RADIOGRAPHY; THREE DIMENSIONAL IMAGING;

AGED; ANTI-OBESITY AGENTS; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; INTRA-ABDOMINAL FAT; LACTONES; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; SUBCUTANEOUS FAT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77951903803     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Foreyt J, Goodrick K. The ultimate triumph of obesity. Lancet 1995; 346: 34-5.
2. Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributed to obesity in the United States. JAMA 1999; 282: 1530-8.
3. Bray GA, Tartagilla LA. Medical strategies in the treatment of obesity. Nature 2000; 404: 672-7.
4. Eckel RH. Obesity and heart disease. Circulation 1997; 96: 3248-50.
5. Megis J, Nathan D, Wilson P, Cupples L, Singer D. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. Ann Intern Med 1998; 128: 524-33.
6. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-7.
7. Sjostrom L, Rissanen A, Anderson T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-72.
8. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-42.
9. Blackburn GL, Waltman BA. Pharmacotherapy to reduce visceral fat. Clin Cornerstone 2005; 7: 52-60.
10. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and sub-cutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart study. Circulation 2007; 116: 39-48.
11. Smith SR, Lovejoy JC, Greenway F, et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolisim 2001; 50: 425-35.
12. Imbeault P, Lemieux S, Prudhomme D, et al. Relationship of visceral adipose tissue to metabolic risk factors for coronary heart disease: is there a contribution of subcutaneous fat cell hypertrophy? Metabolism 1999; 48: 355-62.
13. Arsenault BJ, Lachance D, Lemieux I, et al. Visceral adipose tissue accumulation, cardiorespiratory fitness, and features of the metabolic syndrome. Arch Intern Med 2007; 167: 1518-25.
14. Zamboni M, Turcato E, Armellini F, et al. Sagittal abdominal diameter as a practical predictor of visceral fat. Int J Obes Relat Metab Disord 1998; 22: 655-60.
15. Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73: 460-8.
16. Onat A, Avci GS, Barlan MM, et al. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord 2004; 28: 1018-25.
17. Schoen RE, Thaete FL, Sankey SS, Weissfeld JL, Kuller LH. Sagittal diameter in comparison with single slice CT as a predictor of total visceral adipose tissue volume. Int J Obes Relat Metab Disord 1998; 22: 338-42.
18. Valsamakis G, McTernan PG, Chetty R, et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004; 53: 430-4.
19. Sjostrom L, Kvist H, Cederblad A, Tylen U. Determination of total adipose tissue and body fat in women by computed tomography. Am J Physiol 1986; 250: E736-45.
20. Van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord 1993; 17: 187-96.
21. Kvist H, Chowdhury B, Grangard U, Tylen U, Sjostrom L. Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women. Predictive equations. Am J Clin Nutr 1988; 48: 1351-61.
22. Jensen MD, Kanaley JA, Reed JE, Sheedy PF. Measurements of abdominal and visceral fat with computed tomography and dual-energy X-ray absorptiometry. Am J Clin Nutr 1995; 61: 274-8.
23. Drent ML, Larson I, William-Olsson T, et al. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord 1995; 19: 221-6.
24. Hauptman JB, Jeunet FS, Harmann D. Initial studies in humans with a novel gastrointestinal lipase inhibitor. Am J Clin Nutr 1992; 55: 309-13S.
25. Rimonabant effectively reduces visceral fat in the obese patient as confirmed by abdominal computed tomography scan. Session of the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), 2007, Amsterdam, The Netherlands.